Basilea on track with strong 2025 half-year results

Core Viewpoint - Basilea Pharmaceutica Ltd reported strong financial performance and significant progress in its antibacterial and antifungal portfolio during the first half of 2025, highlighted by the launch of Zevtera in the US and encouraging sales momentum for Cresemba in Japan [2][3]. Financial Performance - Total revenue for H1 2025 reached CHF 104.0 million, a 36.3% increase from CHF 76.3 million in H1 2024 [3][5]. - Royalty income increased by 21.7% to CHF 52.1 million, while product revenue rose to CHF 31.5 million, up from CHF 27.6 million [3][9]. - Operating profit surged by 160% to CHF 24.0 million, with operating cash flow increasing by 29% to CHF 23.1 million [5][7]. Research and Development - Basilea invested CHF 38.3 million in R&D during H1 2025, focusing on ongoing phase 3 studies for fosmanogepix and preparations for a second phase 3 study [4][9]. - The company is advancing its late-stage clinical pipeline with the acquisition of a novel oral phase 3-ready antibiotic for complicated urinary tract infections [2][4]. Future Guidance - For FY 2025, Basilea expects total revenue to increase by 8% to CHF 225 million, with a projected 14% rise in royalty income to CHF 110 million [11][12]. - The company anticipates maintaining a high operating profit level of CHF 50 million despite increased R&D expenses [19]. Cash Position and Debt Management - As of June 30, 2025, Basilea's cash and cash equivalents totaled CHF 132.7 million, significantly up from CHF 69.5 million a year earlier [8][9]. - The company reduced its convertible bonds by 14% to CHF 83 million and increased its net cash position to CHF 50.7 million [8][9].